Establishment and validation of a gasdermin signature to evaluate the immune status and direct risk-group classification in luminal-B breast cancer

Clin Transl Med. 2021 Nov;11(11):e614. doi: 10.1002/ctm2.614.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • BRCA2 Protein / genetics
  • BRCA2 Protein / metabolism
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms / complications
  • Breast Neoplasms / diagnosis*
  • Breast Neoplasms / genetics
  • Female
  • Humans
  • Pore Forming Cytotoxic Proteins / analysis*
  • Pore Forming Cytotoxic Proteins / genetics
  • Proportional Hazards Models
  • Risk Assessment / methods
  • Risk Assessment / standards
  • Risk Assessment / trends*
  • Ubiquitin-Protein Ligases / genetics
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • BRCA2 Protein
  • BRCA2 protein, human
  • Biomarkers, Tumor
  • GSDMA protein, human
  • Pore Forming Cytotoxic Proteins
  • BRAP protein, human
  • Ubiquitin-Protein Ligases